CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK

Priyanka Mehta1, Roderick Murphy2, Saemi Park2

  • 1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Leukemia & Lymphoma
|July 1, 2026
PubMed
Abstract

No abstract available in PubMed .